rss
Evid Based Med doi:10.1136/eb-2012-100992
  • Prevention
  • Systematic review

Hormone therapy not recommended for chronic disease prevention in menopausal women

  1. Nanette K Wenger
  1. Department of Medicine (Cardiology), Emory University School of Medicine, Atlanta, Georgia, USA
  1. Correspondence to : Dr Nanette K Wenger
    Department of Medicine (Cardiology), Emory University School of Medicine, 49 Jesse Hill Jr. Drive, SE Atlanta, GA 30303, USA; nwenger{at}emory.edu

Commentary on:

Context

In 2005, the US Preventive Services Task Force (USPSTF) updated its 2002 hormone replacement therapy recommendations, advising against the routine use of oestrogen and progestin (E+P) and unopposed oestrogen (E) to prevent chronic conditions in menopausal women. Menopausal hormone therapy (MHT) had been commonly prescribed to prevent conditions such as cardiovascular disease, dementia and osteoporosis. Clinical trial data dramatically changed clinical practice. The Heart and Estrogen/Progestin Replacement Study (HERS) examined conjugated equine oestrogen (CEE)+medroxyprogesterone acetate in women with coronary disease; hormone therapy did not decrease coronary events. Primary prevention was studied in the Women's Health Initiative (WHI) trial: E+P or E in women with …

Free Sample

This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of EBM.
View free sample issue >>


Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article